Warm Antibody Autoimmune Hemolytic Anemia

Immunology
4
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
1
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Rigel Pharmaceuticals
Rigel PharmaceuticalsSOUTH SAN FRANCISCO, CA
3 programs
1
2
Fostamatinib disodiumPhase 31 trial
Fostamatinib disodiumPhase 31 trial
Fostamatinib 150 mg bidPhase 21 trial
Active Trials
NCT02612558CompletedEst. Dec 2019
NCT03764618CompletedEst. Apr 2022
NCT04138927Enrolling By InvitationEst. Apr 2024
H
HutchmedChina - Hong Kong
1 program
1
HMPL-523Phase 2/31 trial
Active Trials
NCT05535933Active Not Recruiting110Est. Nov 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Rigel PharmaceuticalsFostamatinib disodium
Rigel PharmaceuticalsFostamatinib disodium
HutchmedHMPL-523
Rigel PharmaceuticalsFostamatinib 150 mg bid

Clinical Trials (4)

Total enrollment: 110 patients across 4 trials

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Start: Oct 2019Est. completion: Apr 2024
Phase 3Enrolling By Invitation

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

Start: Apr 2019Est. completion: Apr 2022
Phase 3Completed

HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Start: Sep 2022Est. completion: Nov 2026110 patients
Phase 2/3Active Not Recruiting
NCT02612558Rigel PharmaceuticalsFostamatinib 150 mg bid

A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)

Start: Jul 2016Est. completion: Dec 2019
Phase 2Completed

Related Jobs in Immunology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space